Trials / Completed
CompletedNCT03597412
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Type 2 Diabetes Mellitus (DM)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 236 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and aafety of rosuvastatin/ezetimibe combination therapy vs. rosuvastatin monotherapy in atherosclerotic cardiovascular disease patients with type 2 diabetes mellitus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvamibe | Rosuvastatin 10mg/Ezetimibe 10mg |
| DRUG | Monorova | Rosuvastatin 20mg |
Timeline
- Start date
- 2018-10-17
- Primary completion
- 2020-08-12
- Completion
- 2020-08-12
- First posted
- 2018-07-24
- Last updated
- 2020-12-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03597412. Inclusion in this directory is not an endorsement.